Here are the 10-Q quarterly reports from Adverum Biotechnologies, Inc. (ADVM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ADVM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADVM filings page.
Adverum Biotechnologies (ADVM) reported Q3 2025 results and outlined pending acquisition terms with Eli Lilly. The company posted a quarterly net loss of $47.7 million (loss per share $2.03) on operating expenses of $48.0 million as research and development rose to $38.9 million. Year‑to‑date net loss was $143.9 million.
Liquidity tightened: cash and cash equivalents were $26.1 million as of September 30, 2025, and operating cash use for the nine months was $109.7 million. Total assets were $72.4 million versus $179.8 million at year‑end, and stockholders’ equity moved to a $(55.7) million deficit. Management disclosed substantial doubt about the company’s ability to continue as a going concern.
On October 24, 2025, Lilly launched a tender offer to acquire all shares for $3.56 in cash per share plus one CVR worth up to $8.91 upon milestones: up to $1.78 on U.S. approval of Ixo‑vec and up to $7.13 if annual worldwide Ixo‑vec net sales exceed $1.0 billion. The company also entered a secured note with Lilly for up to $65.0 million (SOFR + 10%), with $5.0 million funded on October 28 and $15.0 million on November 7. A $10.0 million August private placement added limited cash. Clinical programs advanced with Phase 3 ARTEMIS screening completed and AQUARIUS planned.
Adverum reported accelerating clinical investment alongside a sharply widening operating loss and constrained liquidity. The company recorded a net loss of $49.2 million for the quarter and $96.2 million for the six months, compared with $30.5 million and $57.6 million in the prior-year periods. Cash, cash equivalents and short-term investments totaled $44.4 million at June 30, 2025 and the company used $81.5 million of cash in operations in the six months. Management states available funds, including proceeds from an August 2025 private placement, are expected to fund operations into the fourth quarter of 2025 but are insufficient to provide twelve months of liquidity, which raises substantial doubt about the company’s ability to continue as a going concern.
On the clinical front, Adverum is advancing its lead program, Ixo-vec. The company initiated the ARTEMIS Phase 3 trial in February 2025 and plans a second Phase 3 trial (AQUARIUS) subject to funding. LUNA Phase 2 52-week topline results showed meaningful treatment-burden reductions (annualized anti-VEGF injection reductions of 88% at 6E10 and 92% at 2E11 with injection-free rates of 54% and 69%), and OPTIC long-term data show durable responses out to multi-year follow-up. The company holds several regulatory designations for Ixo-vec (FDA Fast Track and RMAT, EMA PRIME, MHRA Innovation Passport).